Novartis CEO Says FDA Process Could Have Been Handled Better

Login to Listen
(Bloomberg) -- Novartis AG Chief Executive Officer Vas Narasimhan said the company could have handled a furor surrounding its Zolgensma gene therapy better.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.